Merck's Multi-Billion Dollar Partnership with Daiichi Sankyo for Cancer Therapies
Merck has entered into a partnership with Daiichi Sankyo, committing $4 billion upfront, to co-develop and co-commercialize three antibody-drug conjugates (ADCs) from Daiichi's DXd platform. The ADCs target HER3, B7-H3, and CDH6, with the most advanced program set for a BLA filing by the end of March 2024. This partnership adds momentum to the growing ADC space, which has seen blockbuster revenue, data readouts, and increased M&A activity.